MRK

Merck & Co., Inc.

Healthcare
115.67 +0.46 +0.40% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 285.68B
EV —
Shares Out 2.47B
Revenue (ttm) 65.77B
Net Income 8.94B
Beta —
P/E 32.00
Forward P/E —
EPS (ttm) $3.55
P/S 4.35
P/B 6.23
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 6.94%
ROE 18.82%
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin 13.59%
Debt/Eq 1.07
LT Debt/Eq 50.43%
Quick Ratio —
Current Ratio 1.30
Book/sh 18.56
Cash/sh 2.15
Div Yield 2.87%
Div TTM $3.32
Payout Ratio 93.52%
SMA20 0.59%
SMA50 -0.36%
SMA200 11.85%
Volume 5,407,345
Avg Volume 10.47M
Rel Volume —
Perf Week -2.57%
Perf Month 2.23%
Perf Quarter -0.34%
Perf Half Y 15.99%
Perf YTD 9.89%
Perf Year 49.02%
Perf 3Y 2.26%
Perf 5Y 56.08%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.8500
TTM Yield 2.87%
TTM Amount $3.32
Payout Ratio 93.52%
3-Yr Growth (CAGR) 5.42%
5-Yr Growth (CAGR) 5.75%

Last 12 Payouts

Period Ex-Date Amount / Share
Q1 2026 ~2026-03-31 $0.8500
Q4 2025 ~2025-12-30 $0.8500
Q3 2025 ~2025-09-30 $0.8100
Q2 2025 ~2025-06-30 $0.8100
Q1 2025 ~2025-03-31 $0.8100
Q4 2024 ~2024-12-30 $0.8100
Q3 2024 ~2024-09-30 $0.7700
Q2 2024 ~2024-06-30 $0.7700
Q1 2024 ~2024-03-31 $0.7700
Q4 2023 ~2023-12-30 $0.7700
Q3 2023 ~2023-09-30 $0.7300
Q2 2023 ~2023-06-30 $0.7300

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Merck & Co., Inc. is a leading global healthcare company engaged in the business of discovering, developing, producing and marketing a broad range of human and animal health products. The company's human health business, organized as Pharmaceuticals, includes medicines and vaccines across multiple therapeutic areas such as oncology, cardiometabolic and respiratory diseases, immunology, infectious diseases, and vaccines. Key products include KEYTRUDA, an oncology immunotherapy; WINREVAIR, a pulmonary arterial hypertension treatment; GARDASIL vaccines for HPV-related cancers; and other pharmaceuticals. The Animal Health business provides medicines, vaccines, and services for livestock and companion animals, including products for disease prevention and treatment. The company invests significantly in research and development to advance its pipeline, which includes approximately 80 ongoing Phase 3 studies across multiple therapeutic areas. Merck operates globally with a presence in numerous countries and maintains manufacturing facilities domestically and internationally.

Name
Merck & Co., Inc.
Industry
Drug Manufacturers - General
CEO
Robert M. Davis · Chairman, Chief Executive Officer and President
Employees
—
IPO Date
2018-03-01
Phone
908-740-4000
Address
126 East Lincoln Avenue, Rahway, NJ 07065
Website
www.merck.com

Key Executives

Name Title FY Pay
Jennifer Zachary Executive Vice President and General Counsel —
Dean Li, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories —
Sanat Chattopadhyay Executive Vice President and President, Merck Manufacturing Division —
Caroline Litchfield Executive Vice President and Chief Financial Officer —
Robert M. Davis Chairman, Chief Executive Officer and President —

Latest News